AC Immune Stock Price, News & Analysis

AC Immune (NASDAQ: ACIU) has announced a strategic restructuring to optimize its pipeline focus and extend its cash runway. The company will implement a 30% workforce reduction while concentrating on its three clinical-stage active immunotherapy programs and key small molecule programs targeting NLRP3 and Tau.

The restructuring will extend the company's cash runway through Q3 2027, supported by current cash resources of CHF 127.1 million as of June 30, 2025. The company maintains its clinical timeline guidance, with interim data expected from ACI-7104.056 in H2 2025 and ACI-24.060 in H1 2026.

The implementation will be completed by the end of 2025, with cost reductions becoming fully effective in early 2026. Affected employees will receive severance packages and support for new employment opportunities.

AC Immune (NASDAQ: ACIU) reported Q2 2025 financial results and provided updates on its neurodegenerative disease pipeline. The company maintains a strong financial position with CHF 127.1 million in cash, providing runway into Q1 2027. Key highlights include positive interim results from the Phase 2 VacSYn trial of ACI-7104.056 for Parkinson's disease, showing a 20-fold increase in anti-α-syn antibodies.

The company has three active immunotherapies in Phase 2 development, including ACI-24.060 for Alzheimer's disease, with interim results expected in early 2026. Their NLRP3 inhibitor program (ACI-19764) has advanced to IND-enabling studies. Q2 financial results showed contract revenues of CHF 1.3 million and a net loss of CHF 21.2 million, improved from CHF 22.8 million in Q2 2024.

AC Immune reported Q1 2025 financial results, highlighting strong progress in its neurodegenerative disease therapeutics pipeline. The company maintains a solid cash position of CHF 145.7 million, providing funding into Q1 2027.

Key developments include positive interim Phase 2 results for ACI-7104.056, their anti-alpha-synuclein immunotherapy for Parkinson's disease, showing strong immunogenicity and favorable safety. The treatment induced anti-a-syn antibodies over 20-fold higher than placebo levels after four immunizations.

Q1 2025 financials show R&D expenses of CHF 15.9 million (up from CHF 15.2 million in Q1 2024) and G&A expenses of CHF 4.4 million (down from CHF 5.0 million). The company reported a net loss of CHF 19.0 million, compared to CHF 17.9 million in the same period last year.

Multiple milestones are expected throughout 2025, including additional Phase 2 data readouts and potential trial initiations across their therapeutic portfolio.

AC Immune (NASDAQ: ACIU) has reported positive interim results from its Phase 2 VacSYn clinical trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease. The treatment has demonstrated significant efficacy, producing anti-α-synuclein antibody levels over 20-fold higher than placebo after 4 immunizations.

The trial's Part 1 involves over 30 patients randomized at a 3:1 ratio (treatment:placebo). Key findings show that antibody responses were effectively induced at week 6 after 2 immunizations and were further enhanced with additional doses. The treatment has shown a favorable safety profile with no serious adverse events reported, with only mild side effects including injection site reactions and headaches.

Based on upcoming interim results in 2025, including pharmacodynamic and biomarker data, the company may proceed with Part 2 of the trial, expanding to up to 150 patients. This phase will evaluate disease progression through motor and non-motor symptoms, along with digital, imaging, and fluid biomarkers.

AC Immune (NASDAQ: ACIU) has announced multiple presentations at the upcoming International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) in Vienna, Austria, from April 1-5, 2025. The company will host an industry symposium on April 2, focusing on active immunotherapies for neurodegenerative diseases.

The symposium will feature presentations on:

• Disease modification in Parkinson's disease
• ACI-7104.056 Phase 2 trial VacSYn
• ACI-35.030/JNJ2056 Phase 2b Retain study
• ACI-24.060 Phase 1b/2 ABATE study

Additional oral presentations will cover Morphomer® small molecules targeting Tau, Morphomer-antibody drug conjugates, and therapeutic molecules targeting alpha-synuclein aggregation. The event will include presentations from AC Immune leadership, key opinion leaders, and collaboration partners from Johnson & Johnson Innovative Medicine.

AC Immune (NASDAQ: ACIU) reported its full year 2024 financial results, highlighting a landmark deal with Takeda worth $100 million upfront and potential milestones up to $2.1 billion plus royalties for ACI-24.060. The company received a CHF 24.6 million milestone payment from Janssen for enrollment progress in the JNJ-2056 Phase 2b trial.

Key financial metrics include:

• Cash position of CHF 165.5 million, providing funding into Q1 2027
• Contract revenues of CHF 27.3 million in 2024
• R&D expenses increased to CHF 62.6 million
• Net loss of CHF 50.9 million

Clinical progress includes positive interim safety data for ACI-24.060 in Down syndrome patients and encouraging results for ACI-7104.056 in Parkinson's disease. The company expects 2025 total cash expenditure between CHF 75-85 million.

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, has announced its participation in two major investor conferences in March 2025:

• Leerink Partners 2025 Global Healthcare Conference - Management will hold investor meetings on March 10, 2025
• Barclays 27th Annual Global Healthcare Conference - Management will conduct investor meetings on March 11, 2025

Interested parties can arrange one-on-one meetings with AC Immune's management team through their Leerink or Barclays representatives or by contacting AC Immune directly.

AC Immune announced interim safety data from the Phase 1b/2 ABATE trial of ACI-24.060 in individuals with Down syndrome (DS). The trial evaluates an active immunotherapy targeting toxic forms of amyloid beta. Key findings from the first two cohorts receiving low and mid-dose treatments showed:

- No serious adverse events related to the study drug

- No cases of amyloid-related imaging abnormalities (ARIA)

- Subjects treated for up to one year

Based on these encouraging results, AC Immune plans to proceed with the high-dose cohort. The ABATE study is ongoing at sites in the U.S., U.K., and Spain. ACI-24.060 has received Fast Track designation from the FDA for Alzheimer's disease treatment.

AC Immune (NASDAQ: ACIU) announced positive interim results from its Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease. The treatment showed significant efficacy, inducing anti-a-synuclein antibody levels 16-fold higher than placebo after 3 immunizations, with a 100% patient response rate. The trial reported positive safety data with only minor side effects including injection site reactions (49%) and headaches (18%). The study may expand to Part 2 with up to 150 patients in H1 2025, focusing on motor symptoms and biomarkers for potential pivotal study transition.